IR for the long-cycle, milestone-led register
Biotech is the ASX sector where the gap between operational reality and share-price reaction is widest. Trial readouts, regulatory milestones, and partnership announcements have to be communicated with absolute care under Listing Rule 3.1 — and in a way that survives twelve months of milestone-quiet periods. Orca runs IR for listed biotech, med-tech, and diagnostics companies inside that constraint.
Biotech and life sciences
Pre-revenue biotech, med-tech, and diagnostics
The ASX biotech sector spans pre-revenue platforms, post-approval commercial stories, and diagnostics — each with its own communications discipline.
What makes the IR work in this sector hard
Every sector has the disclosure quirks that catch a generalist firm out. The ones we see most in biotech and life sciences:
Milestone-led cadence
Trial readouts and regulatory decisions move the price and the narrative. The disclosure machinery has to be ready, not improvised.
Scientific translation
Endpoints, p-values, hazard ratios — written so a generalist fund manager and a sector specialist both read the same conclusion.
Capital between milestones
Pre-revenue biotechs raise repeatedly. The IR work between raises is what makes the next raise possible.
Partnership and licensing comms
Deal terms, milestone payments, royalty structures — communicated to satisfy both the counterparty confidentiality and disclosure obligations.
What we deliver into biotech and life sciences
Clinical and regulatory announcement framework
Pre-built templates, sign-off chain, and language library so trial readouts and FDA/TGA decisions can be lodged within hours of receipt.
Capital raise communications
Placement, entitlement offer, SPP, and strategic-equity comms — tuned to the milestone calendar.
Partnership and licensing comms
Drafting and ASX lodgement of partnership, licensing, and milestone-payment announcements alongside legal and the partner's communications team.
Investor day and KOL programs
Investor days, KOL panels, and the long-form materials that build conviction through the quiet periods.
Where we typically engage
The recurring announcement and milestone events that shape the sector calendar.
- Clinical trial readouts — Phase I, II, III
- FDA, TGA, EMA approvals and decisions
- Partnership and licensing deals
- Capital raises around milestones
- Strategic reviews and M&A
Services we run most often in this sector
Institutional-Grade Communications
ASX announcements, investor pitch decks, and roadshow coaching for small-mid cap companies — crisp, on-time, and built for how portfolio managers and analysts actually decide.
Competitor and Industry Analysis
Local and international competitor and industry analysis for small-mid cap ASX companies — delivered every Monday, with real-time reports and the emerging themes that move your sector.
Strategy and Tactics
Proactive PR and media strategy for small-mid cap ASX companies — building profile with the media, industry, and investors, securing coverage, amplifying milestones, and managing issues.
Frequently asked
Do you have medical or scientific staff?
No — we work alongside your scientific advisory and chief medical officer. Our seat is the communications translation, not the science.
Can you handle a confidential trial readout?
Yes — that is a core part of the discipline. We have drafted dozens of trial-readout announcements under embargo.
Talk to us about biotech and life sciences
Tell us about your company and where you want the market to be. We will take it from there.